Effect of short-term exposure to zidovudine (AZT) on the expression of mitochondria-related genes in skeletal muscle of neonatal mice

Mitochondrion

Volumn 9, Issue 1, 2009, Pages 9-16

  Desai, Varsha G ^a   Lee, Taewon ^a   Moland, Carrie L ^a   Branham, William S ^a   Von Tungeln, Linda S ^a   Beland, Frederick A ^a   Fuscoe, James C ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Infant B6C3F1 mouse; Mitochondrial functions; Skeletal muscle; Zidovudine (AZT)

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ACYL COENZYME A DEHYDROGENASE; ADENYLATE KINASE; AQUAPORIN 1; AQUAPORIN 3; AQUAPORIN 7; AQUAPORIN 8; CARNITINE ACETYLTRANSFERASE; CARRIER PROTEIN; CELL NUCLEUS DNA; DIHYDROLIPOAMIDE DEHYDROGENASE; DNA DIRECTED DNA POLYMERASE GAMMA; DNA GLYCOSYLTRANSFERASE; ENOYL COENZYME A HYDRATASE; FATTY ACID; GLUCOKINASE; LONG CHAIN FATTY ACID COENZYME A LIGASE; MITOCHONDRIAL CREATINE KINASE; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE; PROTEIN BCL 2; PROTEIN BNIP3; PUMA PROTEIN; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE COMPLEX; RIBOSOME PROTEIN; THYMIDINE KINASE; ZIDOVUDINE;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DOSE COMPARISON; FATTY ACID METABOLISM; FEMALE; GENETIC TRANSCRIPTION; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION CONTROL; MALE; MICROARRAY ANALYSIS; MITOCHONDRIAL MEMBRANE; MOUSE; MUSCLE FUNCTION; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PERINATAL DRUG EXPOSURE; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SINGLE DRUG DOSE; SKELETAL MUSCLE; TIME; UNINDEXED SEQUENCE; VERTICAL TRANSMISSION;

ANIMALS; APOPTOSIS; DNA, MITOCHONDRIAL; FEMALE; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MITOCHONDRIA; MUSCLE, SKELETAL; REVERSE TRANSCRIPTASE INHIBITORS; SEX FACTORS; TIME FACTORS; ZIDOVUDINE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 60249089536     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mito.2008.09.002     Document Type: Article

References (44)

1. Arnaudo E., Dalakas M., Shanske S., Moraes C.T., DiMauro S., et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337 (1991) 508-510
2. Bishop J.B., Tani Y., Witt K., Johnson J.A., Peddada S., Dunnick J., and Nyska A. Mitochondrial damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicol. Sci. 81 (2004) 512-517
3. Blanche S., Tardieu M., Rustin P., Slama A., Barret B., et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354 (1999) 1084-1089
4. Brinkman K., ter Hofstede H.J., Burger D.M., Smeitink J.A., and Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12 (1998) 1735-1744
5. Bruick R.K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. USA 97 (2000) 9082-9087
6. Center for Disease Control (CDC) and Prevention, 2006. Achievements in public health: reduction in perinatal transmission of HIV infection-United States, 1985-2005. MMWR 55, 592-597.
7. Center for Disease Control (CDC) and Prevention, 2008. Public health services task force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States, p. 52. Available from: http://www.aidsinfo.nih.gov/guidelines/.
8. Center for Drug Evaluation and Research (CDER), 2005. Pharmacology and toxicology, guidance for industry. Estimating the maximum safe dose in initial clinical trials for therapeutics in adult healthy volunteers, p. 7. Available from: http://www.fda.gov/cder/guidance/index.htm.
9. Chan S.S., Santos J.H., Meyer J.N., Mandavilli B.S., Cook Jr. D.L., et al. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. Environ. Mol. Mutagen. 48 (2007) 190-200
10. Clark R.A., and Squires K.E. Gender-specific considerations in the antiretroviral management of HIV-infected women. Expert Rev. Anti-Infect. Ther. 3 (2005) 213-227
11. Cooper E.R., Charurat M., Mofenson L., Hanson I.C., Pitt J., et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. 29 (2002) 484-494
12. Dalakas M.C., Leon-Monzon M.E., Bernardini I., Gahl W.A., and Jay C.A. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann. Neurol. 35 (1994) 482-487
13. de la Asuncion J.G., del Olmo M.L., Sastre J., Millan A., Pellin A., et al. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J. Clin. Invest. 102 (1998) 4-9
14. Delongchamp R.R., Lee T., and Velasco C. A method for computing the overall statistical significance of a treatment effect among a group of genes. BMC Bioinform. 7 Suppl2 (2006) S11
15. Desai V.G., Moland C.L., Branham W.S., Delongchamp R.R., Fang H., Duffy P.H., Peterson C.A., Beggs M.L., and Fuscoe J.C. Changes in expression level of genes as a function of time of day in the liver of rats. Mutat. Res. 549 (2004) 115-129
16. Desai V.G., Lee T., Delongchamp R.R., Moland C.L., Branham W.S., Fuscoe J.C., and Leakey J.E. Development of mitochondria-specific mouse oligonucleotide microarray and validation of data by real-time PCR. Mitochondrion 7 (2007) 322-329
17. de Souza-Pinto N.C., Eide L., Hogue B.A., Thybo T., Stevnsner T., et al. Repair of 8-oxodeoxyguanosine lesions in mitochondrial DNA depends on the oxoguanine DNA glycosylase (OGG1) gene and 8-oxoguanine accumulates in the mitochondrial DNA of OGG1-defective mice. Cancer Res. 61 (2001) 5378-5381
18. Divi R.L., Haverkos K.J., Humsi J.A., Shockley M.E., Thamire C., et al. Morphological and molecular course of mitochondrial pathology in cultured human cells exposed long-term to zidovudine. Environ. Mol. Mutagen. 48 (2007) 179-189
19. Divi R.L., Leonard S.L., Kuo M.M., Nagashima K., Thamire C., et al. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ. Mol. Mutagen. 48 (2007) 201-209
20. Divi R.L., Leonard S.L., Walker B.L., Kuo M.M., Shockley M.E., et al. Erythrocebus patas monkey offspring exposed perinatally to NRTIs sustain skeletal muscle mitochondrial compromise at birth and at 1 year of age. Toxicol. Sci. 99 (2007) 203-213
21. Dzeja P.P., Zeleznikar R.J., and Goldberg N.D. Suppression of creatine kinase-catalyzed phosphotransfer results in increased phosphoryl transfer by adenylate kinase in intact skeletal muscle. J. Biol. Chem. 271 (1996) 12847-12851
22. Gerschenson M., and Poirier M.C. Fetal patas monkeys sustain mitochondrial toxicity as a result of in utero zidovudine exposure. Ann. N. Y. Acad. Sci. 918 (2000) 269-281
23. Gerschenson M., Nguyen V., Ewings E.L., Ceresa A., Shaw J.A., et al. Mitochondrial toxicity in Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res. Hum. Retrov. 20 (2004) 91-100
24. Kubasiak L.A., Hernandez O.M., Bishopric N.H., and Webster K.A. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc. Natl. Acad. Sci. USA 99 (2002) 12825-12830
25. Lambert J.S., Nogueira S.A., Abreu T., Machado E.S., Costa T.P., et al. A pilot study to evaluate the safety and feasibility of the administration of AZT/3TC fixed dose combination to HIV infected pregnant women and their infants in Rio de Janeiro, Brazil. Sex Transm. Infect. 79 (2003) 448-452
26. Lange H., Kispal G., and Lill R. Mechanism of iron transport to the site of heme synthesis inside yeast mitochondria. J. Biol. Chem. 274 (1999) 18989-18996
27. Lebrecht D., Deveaud C., Beauvoit B., Bonnet J., Kirschner J., and Walker U.A. Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice. Arthritis Rheum. 58 (2008) 318-326
28. Lewis W. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarification and persistent clinical questions. Antiviral Res. 58 (2003) 189-197
29. Lewis W., Gonzalez B., Chomyn A., and Papoian T. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J. Clin. Invest. 89 (1992) 1354-1360
30. Masini A., Scotti C., Calligaro A., Cazzalini O., Stivala L.A., et al. Zidovudin-induced experimental myopathy: dual mechanism of mitochondrial damage. J. Neurol. 166 (1999) 131-140
31. Mhiri C., Baudrimont M., Bonne G., Geny C., Degoul F., et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann. Neurol. 29 (1991) 606-614
32. Modica-Napolitano J.S. AZT causes tissue-specific inhibition of mitochondrial bioenergetic function. Biochem. Biophys. Res. Commun. 194 (1993) 170-177
33. Mofenson L.M., and McIntyre J.A. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 355 (2000) 2237-2244
34. Moyle G.J., Datta D., Mandalia S., Morlese J., Asboe D., et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility, and possible risk factors. AIDS 16 (2002) 1341-1349
35. Peters B.S., Winer J., Landon D.N., Stotter A., and Pinching A.J. Mitochondrial myopathy with chronic zidovudine therapy in AIDS. Q. J. Med. 86 (1993) 5-15
36. Poirier M.C., Divi R.L., Al-Harthi L., Olivero O.A., Nguyen V., et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J. Acquir. Immune Defic. Syndr. 33 (2003) 175-183
37. Regula K.M., Ens K., and Kirshenbaum L.A. Inducible expression of BNIP3 provides mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ. Res. 91 (2002) 226-231
38. Scruggs E.R., and Dirks Naylor A.J. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology 82 (2008) 83-88
39. Shah I. Adverse effects of antiretroviral therapy in HIV-1 infected children. J. Trop. Pediatr. 52 (2006) 244-248
40. Sugden M.C., and Holness M.J. Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am. J. Physiol. Endocrinol. Metab. 284 (2003) E855-E862
41. Vande Velde C., Cizeau J., Dubik D., Alimonti J., Brown T., et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol. Cell. Biol. 20 (2000) 5454-5468
42. Von Tungeln L.S., Williams L.D., Doerge D.R., Shaddock J.G., McGarrity L.J., et al. Transplacental drug transfer and frequency of Tk and Hprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine. Environ. Mol. Mutagen. 48 (2007) 258-269
43. Walker D.M., Poirier M.C., Campen M.J., Cook Jr. D.L., Divi R.L., et al. Persistence of mitochondrial toxicity in hearts of female B6C3F1 mice exposed in utero to 3′-azido-3′-deoxythymidine. Cardiovasc. Toxicol. 4 (2004) 133-153
44. Zeleznikar R.J., Dzeja P.P., and Goldberg N.D. Adenylate kinase-catalyzed phosphoryl transfer couples ATP utilization with its generation by glycolysis in intact muscle. J. Biol. Chem. 270 (1995) 7311-7319